NCT04800991已完成不适用
A Pilot Study to Evaluate the Feasibility and Efficacy of Digital Health Technology for Postoperative Care With Gastrectomy-Treated Patients in Gastric Cancer
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators
研究概览
简要总结
The objective of this pilot study is to evaluate the feasibility and efficacy of Rhexium Onco Nutrition, HDT-202 for post-operative care in patients who have undergone gastrectomy.
详细描述
- A total of 4 visits will be performed.
- At the screening visit,subject's written informed consent, assessing the inclusion/exclusion criteria and assigning enrollment numbers to eligible subjects, demographic information taking, medical history/medication history taking, vital signs measuring, physical examination, height and body weight measuring, instructing how to install/use the investigational device, and administering quality of life questionnaires.
- During the treatment period, a total of 3 visits will be performed. To evaluate feasibility and efficacy, the following procedures will be carried out: vital signs measuring, physical examination, nutrition assessment/consultation, evaluation of feasibility for 'subjects', evaluation of feasibility for 'investigators', and adverse events (AEs)/concomitant medications checking and collecting.
- During the treatment period, telephone monitoring is conducted depending on the compliance of subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient who voluntarily signs the informed consent form for this study
- •Age of ≥19 years old
- •Patient who has undergone therapeutic gastrectomy after a diagnosis of gastric cancer
- •Able to eat food orally after gastrectomy
- •Patient who possesses an Android OS based mobile device and is capable of using the investigational device.
排除标准
- •Other cancer or metastasis documented within 5 years prior to screening
- •Ongoing or planned enteral tube feeding or total parenteral nutrition
- •Other clinically significant medical or psychiatric findings based on which the individual is considered by the investigator to be ineligible
- •Individual who possesses a mobile device on which the application is unable to be installed and/or run normally for technical reasons
- •Individual who, in the opinion of the investigator, has difficulty understanding how to use the investigational device or is unlikely to comply with other study procedures
研究组 & 干预措施
Rhexium Onco Nutrition(HDT-202)
Experimental
"subject mobile application" and "Investigator web portal" with no invasive action on the human body
干预措施: Rhexium Onco Nutrition (Device)
结局指标
主要结局
Score of each domain of the 'feasibility assessment of the investigational device (website)' questionnaire for investigators
时间窗: Week 6 (Visit 3)
higher scores mean a better outcome
Score of each domain of the 'feasibility assessment of the investigational device (application)' questionnaire for subjects
时间窗: Week 10 (Visit 4)
higher scores mean a better outcome
Score of each domain of the 'feasibility assessment of the investigational device (application)' questionnaire for subjects
时间窗: Week 2 (Visit 2)
higher scores mean a better outcome
Score of each domain of the 'feasibility assessment of the investigational device (application)' questionnaire for subjects
时间窗: Week 6 (Visit 3),
higher scores mean a better outcome
次要结局
- Change from baseline (Visit 1) in 'KOQUSS Index' score(baseline (Visit 1), Week 10 (Visit 4))
- Change from baseline (Visit 1) in 'EORTC QLQ-C30' score(baseline (Visit 1), Week 10 (Visit 4))
- Change from baseline (Visit 1) in 'EORTC QLQ-STO22' score(baseline (Visit 1), Week 10 (Visit 4))
- The investigational device(application) usage compliance by age(Week 10 (Visit 4))
- The investigational device(application) usage compliance by body mass index [BMI] before discharge from hospital(Week 10 (Visit 4))
- Frequency of each symptom between visits after using the investigational device (application)(Week 2 (Visit 2), Week 6 (Visit 3), Week 10 (Visit 4))
- The investigational device(application) usage compliance by stage of disease(Week 10 (Visit 4))
- The investigational device(application) usage compliance by status of postoperative anticancer therapy(Week 10 (Visit 4))
- The investigational device(application) usage compliance by underlying disease(Week 10 (Visit 4))
- The investigational device(application) usage compliance by gender(Week 10 (Visit 4))
- The investigational device(application) usage compliance by surgery(Week 10 (Visit 4))
- Correlation between change from Day 1 in body weight at Week 10 (Visit 4) and calory goal achievement rate(Week 10 (Visit 4))
- Correlation between change from Day 1 in body weight at Week 10 (Visit 4) and protein intake goal achievement rate(Week 10 (Visit 4))
研究者
Han-Kwang Yang
Professor
Seoul National University Hospital
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin LymphomaNon Hodgkin LymphomaNCT03688451Tahir Latif20
终止
1 期
Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent GlioblastomaGlioblastomaNCT02648633University of Virginia4
已完成
不适用
Testing the Feasibility and Preliminary Effect of Summer CampChildhood Obesity PreventionNCT04085965The Miriam Hospital94
已完成
不适用
Food Addiction Clinical Treatment ProgramFood AddictionNCT04373343Wake Forest University Health Sciences2
招募中
早期 1 期
Neratinib in Combination With Ruxolitinib in Patients With mTNBCMetastatic Triple-Negative Breast CarcinomaBreast CancerNCT06008275Baylor Research Institute20